Основной причиной неудачного исхода хирургического лечения хронического дакриоцистита является рубцевание вновь образованного искусственного соустья — дакриостомы. Данный исход обусловлен продолжающейся активностью миофибробластов, приводящей к формированию грубого рубца. Среди лекарственных средств предотвращения рубцевания в настоящее время наибольшую распространенность получил противоопухолевый антибиотик митомицин С. Тем не менее противоречивые данные об эффективности этого препарата обусловливают необходимость его изучения, а также поиска альтернативных лекарственных средств, способных предотвратить рубцевание. За последние годы достигнуты определенные успехи в создании новых антифибротических препаратов, относящихся к группам моноклональных антител, малых молекул РНК и других средств генной терапии, наночастиц и низкомолекулярных препаратов. В настоящем обзоре представлены имеющиеся сведения об эффективности данных препаратов, а также о перспективах их применения в дакриологии.
In recent years, the use of chemotherapeutic agents in the treatment of cancer became more common. At the same time, the number of complications associated with this is also increasing. Among the rare complications of therapy with some antitumor drugs is the formation of secondary acquired nasolacrimal duct obstruction. The aim was to analyze and systematize information about secondary acquired nasolacrimal duct obstruction due to the toxic effect of antitumor drugs. Materials and methods. The authors analyzed the literature available in the MEDLINE and RSCI search engines in February 2021. The analysis included 55 publications. Results. In the literature, there are indications that such antitumor drugs as 5-fluorouracil and similar drugs, mitomycin C, as well as therapy with radioactive iodine, are characterized by the possibility of developing complications in the form of secondary acquired nasolacrimal duct obstruction. Preliminary screening of the drainage function of the tear ducts, as well as prescribing of local anti-inflammatory and antibacterial treatment in the form of instillations in the conjunctival sac can help to reduce the risk of complications. This explains the need to recommend patients to consult an ophthalmologist if there are relevant complaints before or during treatment. In the absence of timely treatment, obstruction of the tear ducts often becomes an indication for reconstructive interventions. Conclusion. Secondary acquired nasolacrimal duct obstruction is one of the rare, but systematically occurring complications of antitumor therapy. To date, the pathogenesis of these complications is not fully understood, and some of the data is contradictory. In the future, the accumulation of knowledge concerning the pathogenesis of this complication will contribute to the development of personalized methods of prevention.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.